Guangdong Huawei Testing Co., Ltd. is jointly established by Guangzhou Institute of Microbiology, Guangdong South China New Drug Creation Co., Ltd., and Guangdong Micro Coarse Investment Center (General Partnership). Guangzhou Institute of Microbiology, an investment holding company, is a technology development research institute mainly engaged in research, product development, and technical services in the fields of inspection and testing, biopharmaceuticals, microbiology, etc. It passed the Metrology Certification (CMA) in 1998, the Laboratory Accreditation Service of China National Accreditation Service for Conformity Assessment (CNAS) in 2003, and the Food Inspection Agency Qualification Certification (CMAF) in 2011. It meets the requirements of ISO/IEC 17025RB/T 214 management system and has rich experience and certain influence in the field of third-party testing. The investment partner Guangdong Huanan New Drug Creation Co., Ltd. is an enterprise engaged in new drug screening, evaluation, testing, new drug research and development, and technical services. It has rich experience in new drug project research and development, new drug creation and technical services. In order to promote the enhancement and development of the independent innovation capability of the national biopharmaceutical industry in the Guangdong Hong Kong Macao Greater Bay Area, while expanding the testing business sector related to the big health industry, and integrating the advantages of various resources such as talent, equipment, and funds, the three parties jointly invested in the registration and establishment of Guangdong Huawei Testing Technology Co., Ltd. in July 2020.